Activity of the Human Rhinovirus 3C Protease Studied in Various Buffers, Additives and Detergents Solutions for Recombinant Protein Production

Ullah, Raheem; Shah, Majid Ali; Tufail, Soban; Ismat, Fouzia; Imran, Muhammad; Iqbal, Mazhar; Mirza, Osman Asghar; Rhaman, Moazur

Published in:
PloS one

DOI:
10.1371/journal.pone.0153436

Publication date:
2016

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (APA):
Ullah, R., Shah, M. A., Tufail, S., Ismat, F., Imran, M., Iqbal, M., ... Rhaman, M. (2016). Activity of the Human Rhinovirus 3C Protease Studied in Various Buffers, Additives and Detergents Solutions for Recombinant Protein Production. DOI: 10.1371/journal.pone.0153436
Activity of the Human Rhinovirus 3C Protease Studied in Various Buffers, Additives and Detergents Solutions for Recombinant Protein Production

Raheem Ullah1,2, Majid Ali Shah1,2, Soban Tufail1, Fouzia Ismat1, Muhammad Imran1*, Mazhar Iqbal1,2, Osman Mirza3, Moazur Rahman1,2*

1 Drug Discovery and Structural Biology group, Health Biotechnology Division, National Institute for Biotechnology and Genetic Engineering (NIBGE), Faisalabad, Pakistan, 2 Pakistan Institute of Engineering and Applied Sciences, P.O. Nilore, Islamabad, Pakistan, 3 Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

* These authors contributed equally to this work.
¤ Current address: Forman Christian College (A Chartered University), Lahore, Pakistan
* moazur.rahman@fulbrightmail.org; moaz@nibge.org

Abstract

Proteases are widely used to remove affinity and solubility tags from recombinant proteins to avoid potential interference of these tags with the structure and function of the fusion partner. In recent years, great interest has been seen in use of the human rhinovirus 3C protease owing to its stringent sequence specificity and enhanced activity. Like other proteases, activity of the human rhinovirus 3C protease can be affected in part by the buffer components and additives that are generally employed for purification and stabilization of proteins, hence, necessitate their removal by tedious and time-consuming procedures before proteolysis can occur. To address this issue, we examined the effect of elution buffers used for common affinity based purifications, salt ions, stability/solubility and reducing agents, and detergents on the activity of the human rhinovirus 3C protease using three different fusion proteins at 4°C, a temperature of choice for purification of many proteins. The results show that the human rhinovirus 3C protease performs better at 4°C than the frequently used tobacco etch virus protease and its activity was insensitive to most of the experimental conditions tested. Though number of fusion proteins tested is limited, we expect that these findings will facilitate the use of the human rhinovirus 3C protease in recombinant protein production for pharmaceutical and biotechnological applications.

Introduction

Affinity purification and solubility enhancement tags are essential tools that aid in the overexpression and downstream processing of recombinant proteins [1, 2]. Some tags do not alter the structural and functional integrity of the target protein; however, a large number do and it is
essential to remove them by proteolytic cleavage. Thus, in certain cases, the choice of tags and the design of the recognition sites for proteases that will remove them become critical though cleavage of the protease site could largely depends on the nature of fusion protein [3]. Specific and nonspecific proteases are used to remove tags. Proteases with specific recognition sites include human rhinovirus 3C protease (HRV 3C), tobacco etch virus (TEV) protease, factor Xa, thrombin, enterokinase and SUMOstar protease [3, 4]. TEV protease is a 27 kDa catalytic domain of the nuclear inclusion-a protease. It cuts efficiently between glutamine and glycine in the canonical recognition site ENLYFQ/G. Several features contributed to the widespread use of TEV protease: (1) stringent cleavage-sequence specificity, (2) post-cleavage release of the target protein with, at the most, an added G to the N-terminus [5], (3) rapid in-house production and (4) optimal activity in a variety of buffers and detergent solutions [4, 5]. A second well-known protease with similar cleavage stringency is the HRV 3C protease or PreScission™ protease. HRV 3C protease cleaves between glutamine and glycine of the canonical site LEVLFQ/GP [1, 4, 6, 7]. To our knowledge no systematic study has been reported on the activity of HRV 3C protease under different experimental conditions; however, it has been suggested that the activity of HRV 3C protease is comparable to that of TEV protease [8] and that it has an increased activity 4°C [1, 2]. Despite an exhaustive literature search, we could not find a comparative study on the temperature-dependent activity of these enzymes.

Finding the appropriate buffer composition and additives (salts, sorbitol, trehalose, glycerol, arginine, proline, reducing agents and detergents) is key for the extraction and the purification of natural and recombinant proteins [9–11] and to increase their stability and solubility [9, 10, 12]. The composition of the buffer used, including any required additives, may affect the protease activity, either by a direct inhibition of the protease or by blocking the cleavage site [13]. A buffer exchange for a standard protease buffer may provide a solution; however, such procedures can be tedious, time consuming and may affect the stability of the target protein. Thus, there is great interest in proteases that are active in a wide variety of buffer solutions and temperatures to enable their exploitation for the cleavage of many recombinant proteins from their tags. Here, we have compared the activity of the HRV 3C protease to the more widely used TEV protease against a set of three fusion proteins, i) a soluble domain of a human metal-ion transport protein (designated as MTD), ii) a beta C1 protein encoded by betasatellites associated with begomoviruses and iii) a 100K protein of fowl adenovirus. These proteins were selected owing to their different nature and high production yield. Moreover, we have studied the effect of frequently used additives on the activity of the HRV 3C protease at 4°C, the temperature of choice for handling most recombinant proteins. Though number of fusion proteins tested is limited, we anticipate that the obtained results will facilitate the use of the HRV 3C protease for the cleavage of fusion tags in the production of recombinant proteins.

**Materials and Methods**

**Construction of TEV and HRV 3C protease cleavable clones**

HRV 3C protease cleavable clone was created by modifying pKLD116 (pKLD116-V2-TEV; generated using primers V2-TEV-F/V2-TEV-R listed in Table 1) [14, 15], which contains a His8-tag, an extended linker (MSTLESSGAASG), maltose binding protein (MBP) and a TEV protease cleavable site upstream from the multiple cloning site. The nucleotide sequence that encodes for the TEV protease cleavable site (ENLYFQ/G) was replaced in pKLD116-V2-TEV with the sequence of the HRV 3C protease cleavable site (LEVLFQ/GP) using the primers HRV-3C-F and HRV-3C-R to generate the construct pKLD116-V2-HRV 3C (Table 1). Using pKLD116-V2-TEV and pKLD116-V2-HRV 3C vectors, protease cleavable expression constructs for a 10 kDa soluble domain of a human metal-ion transport protein (UniprotKB...
Q8IWU4) (designated as MTD), a 14 kDa beta C1 protein (Q91F52) encoded by betasatellites associated with begomoviruses were created using respective primers and restriction enzymes, described in Table 1. For a 89 kDa 100K protein (E1Y6P4) of fowl adenovirus, protease cleavable clones were generated by inserting the coding sequence of 100K into the multiple cloning site of pET28a-HRV 3C and pET28a-TEV, respectively (Table 1), in reading with 5' His8-HRV 3C or His8-TEV sequences. All cloning steps were performed in the Escherichia coli strain OmniMAX™2T1 (Invitrogen) and constructs were confirmed by DNA sequencing.

Expression and purification

Cell culture conditions for expression of the HRV 3C, TEV protease (wild type) and protease cleavable proteins, MTD, beta C1 and 100K are described in Table 2. E. coli cells containing over-expressed HRV 3C protease were resuspended in 20 mM Tris-HCl pH 8.0 containing 500 mM NaCl, 5 mM imidazole and 4 mM β-mercaptoethanol (β-ME) (buffer A) whereas TEV protease containing cells of E. coli were resuspended in 20 mM Tris-HCl pH 8.0 containing 500 mM NaCl, 20 mM imidazole and 10% glycerol (buffer B). Resuspended cells were broken by a Cell disruptor (Constant Systems Ltd, UK) at pressure of 20 kpsi and the cell lysate was spun at 12,000×g, 4°C for 30 min to remove unbroken cells, cell debris or inclusion bodies (if any). The supernatant was passed twice through a Nickel-nitrilotriacetate agarose column equilibrated with the respective resuspension buffers and washed with 25 column volume (CV) of their respective wash buffers (buffer A with 25 mM imidazole and buffer B with 20 mM imidazole). Proteins were eluted in their respective buffers A and B with 250 mM and 500 mM imidazole, respectively. Purified HRV 3C and TEV proteases were dialyzed against 20 mM Tris-HCl pH 7.5 containing 150 mM NaCl, 50% glycerol, 4 mM β-ME and 5 mM EDTA (storage buffer). The protein concentrations were measured by a Bradford assay [18], aliquoted (4 mg per mL) and stored at -20°C until further use.

E. coli cells containing overexpressed protease cleavable proteins His₈-MBP-HRV 3C-MTD, His₈-MBP-TEV-MTD, His₈-MBP-HRV 3C-beta C1, His₈-MBP-TEV-beta C1, His₈-HRV 3C-

Table 1. List of oligonucleotides used for cloning.

| Vector name | Primer Name | Primer sequence |
|-------------|-------------|-----------------|
| pKLD116-V2-TEV | V2-TEV-F | 5'-CACCATATGTCCACGTGAAGGACACGGCCGCGGTCC-3' |
| pKLD116-V2-TEV | V2-TEV-R | 5'-TTTCCAGGGTGGACATATGGGTGGGTGGATGGTGA-3' |
| pKLD116-V2-HRV 3C | HRV-3C-F | 5'-CTGTGAAGTCTGTGTCAGGCGTGCCCGGTCTAAGGTGTCG-3' |
| pKLD116-V2-HRV 3C | HRV-3C-R | 5'-GCCGAACCTGGAACAGincreasesACTCCAGACTATGTTGGTGCACC-3' |
| pKLD116-V2-HRV 3C-MTD or pKLD116-V2-TEV-MTD | MTD-F | 5'-CCAGGCTCGAAGCCGATTAAGTGCTGTGA-3' |
| pKLD116-V2-HRV 3C-betaC1 or pKLD116-V2-TEV-betaC1 | betaC1-F | 5'-ACGAAGCCTGATGACACCGAGCGGAACAC-3' |
| pET28a-HRV 3C-100K or pET28a-TEV-100K | betaC1-R | 5'-GCATGCTAAGGTCTACAGGGGTCTCAGAG-3' |

The underlined nucleotides in the primer sequences represent introduced nuclease restriction sites, and the overhangs at the 5'-ends were incorporated to facilitate nuclease digestion.

doi:10.1371/journal.pone.0153436.t001
100K or His8-TEV-100K were resuspended in 20 mM Tris-HCl pH 7.5 containing 300 mM NaCl, 5 mM imidazole and 4 mM β-ME (buffer C). Resuspended cells were broken by a Cell disruptor (Constant Systems Ltd, UK) at pressure of 20 kpsi and the cell lysate was spun at 12,000×g, 4°C for 30 min to remove unbroken cells, cell debris or inclusion bodies (if any). The supernatant was passed twice through a Nickel-nitrilotriacetate agarose column equilibrated with the respective resuspension buffers and washed with 25 column volume (CV) of wash buffers (buffer C with 30 mM imidazole). Proteins were eluted in buffer C containing 150 mM imidazole and 100 mM NaCl. Purified proteins were dialysed against 20 mM Tris-HCl pH 7.5 containing 150 mM NaCl. The protein concentrations were measured by a Bradford assay [18], aliquoted (4 mg per mL) and stored at -20°C until further use.

Optimization of cleavage conditions for HRV 3C and TEV protease
Protease cleavable proteins (each 50 μg), MTD (His8-MBP-HRV 3C-MTD or His8-MBP-TEV-MTD), beta C1 (His8-MBP-HRV 3C-beta C1 or His8-MBP-TEV-beta C1) and 100K (His8-HRV 3C-100K or His8-TEV-100K) were incubated with HRV 3C or TEV protease (each 2 μg) at a ratio of 50:1 (w/w) in 20 mM Tris-HCl pH 7.5, 150 mM NaCl and 2 mM β-ME in a total volume of 100 μl at 25°C and 4°C. After 1, 2, 4, 8 and 16 hr aliquots were removed from the cleavage reaction, mixed with SDS-PAGE sample buffer (125 mM Tris-HCl pH 6.8 containing 2.5% (w/v) sodium dodecyl sulfate, 0.1% (w/v) ethylenediamine tetraacetate, 12.5% (v/v) glycerol and 0.1% (w/v) bromophenol blue) and stored at -20°C until analyzed. For analysis, 5 μl aliquots of cleavage reaction mixture were loaded in each lane and fusion proteins corresponding to MTD/beta C1 and 100K were resolved using 12% and 10% SDS-PAGE, respectively.

Analysis of activity of HRV 3C protease in various buffers, additives and detergent solutions
The effect on the activity of HRV 3C protease was investigated at 4°C for the following buffers and additives: (1) frequently used buffers for the elution of polyhistidine-tagged (50 mM
Na₂HPO₄, 0.3 M NaCl, 300 mM imidazole, pH 8.0), maltose binding protein (MBP) -tagged (20 mM Tris—HCl pH 7.4 containing 200 mM NaCl, 1 mM EDTA, 1 mM DTT and 10 mM maltose), glutathione-s-transferase (GST) -tagged (50 mM Tris—HCl, 10 mM reduced glutathione, pH 8.0) or Strep-tagged (50 mM Tris—HCl, 150 mM NaCl, 1 mM EDTA, 2.5 mM desthiobiotin or biotin, pH 8.0) proteins from the relevant affinity resins; (2) salts (NaCl, KCl, CaCl₂, MgCl₂, MgSO₄, ZnSO₄); (3) protein stabilizing/solubilizing agents (sorbitol, trehalose, glycerol, arginine and proline); (4) denaturants (sodium dodecyl sulfate, guanidine-HCl and urea); (5) reducing agents (β-ME, dithiothreitol (DTT), tris(2-carboxyethyl) phosphine (TCEP)); and (6) detergents (see Table 3). His8-MBP-HRV 3C-MTD was incubated with HRV 3C protease at a ratio of 1:50 (w/w) at 4°C for 4 hr in 20 mM Tris-HCl pH 7.5 containing 150 mM NaCl and 2 mM β-ME. The reaction was terminated by the addition of SDS-PAGE sample buffer and samples were stored at –20°C until analyzed. The HRV 3C protease cleavage efficiency was estimated visually from SDS-PAGE gels stained with Coomassie Brilliant Blue.

Results and Discussion

Protease cleavable proteins His₈-MBP-HRV 3C-MTD or His₈-MBP-TEV-MTD, His₈-MBP-HRV 3C-betaC1 or His₈-MBP-TEV-beta C1 and His₈-HRV 3C-100K or His₈-TEV-100K have calculated molecular masses of ~ 55.2 kDa, ~ 59.2 kDa and ~ 91 kDa, respectively. Molecular masses of proteins were calculated using the ExPASy Bioinformatic Portal, http://web.expasy.org/compute_pi/. All proteins were produced by recombinant means as described in materials and methods. Cleavage of the target fusion proteins with the HRV 3C or TEV protease releases two major protein bands of ~ 45 kDa (His₈-MBP) and ~ 10 kDa (MTD), ~ 45 kDa (His₈-MBP) and 14 kDa (beta C1), and ~ 89 kDa (100K) and ~ 2 kDa (His₈), respectively (Fig 1). For clarity, we only show the bands corresponding to the uncut fusion proteins and large size cut fragments of the fusion proteins in subsequent SDS-polyacrylamide gels.

We compared the activities of the HRV 3C and TEV proteases towards their three target proteins at 25°C and 4°C. Fig 2 shows that, whilst TEV protease efficiently cleaves the target proteins except His₈-TEV-100K after prolonged incubation at 25°C, it was inefficient to do so even after 16 hr at 4°C. In contrast, HRV 3C protease efficiently cleaved all the three fusion proteins after 4 hr at both tested temperatures. Since many recombinant proteins require handling at 4°C, starting from protein purification through to downstream processing, the superior cleavage properties of HRV 3C protease over TEV protease demonstrate the potential to use HRV 3C protease for recombinant protein production [19]. In addition, HRV 3C protease should also be the protease of choice at 25°C, as our experiments show that its activity at higher temperatures is also superior to that of TEV protease (Fig 2).

To further assess the wide applicability of HRV 3C protease, we tested the effect of the buffer composition on the activity. HRV 3C protease cleaved His₈-MBP-HRV 3C-MTD efficiently upon 4 hr of incubation at 4°C in each of the four standard buffers used for the elution of poly-His-, GST-, MBP- and Strep-tagged fusion proteins [1, 20–23] (Fig 3). This indicates the robustness of the HRV 3C cleavage protein in a variety of buffers; hence eliminating the time consuming process of desalting or dialysis. Furthermore, rapid cleavage by HRV 3C protease limits compromising target protein integrity. The broad cleavage efficiency of HRV 3C protease identifies it as the protease of choice. In cases where the target protease cleavable protein is unstable in the elution buffer (for example, due to a high imidazole concentration in purifications using Ni-NTA technology), exchange into a suitable buffer by dialysis or any other procedure may be done before cleavage is performed.

Salt ions affect the stability, solubility, structure and function of proteins in various ways [11, 19, 24]. One of these mechanisms is the interaction of salt ions with counter-ions on the
Table 3. Effect of detergents on the activity of the HRV 3C protease activity.

| S.No. | Chemical Name                  | Critical micelle concentration | Activity |
|-------|--------------------------------|--------------------------------|----------|
| 1     | ANAPOE<sup>1</sup>-80         | 1% w/v                         | +++      |
| 2     | n-Tetradecyl-β-D-maltoside    | 0.0335 mM                      | +++      |
| 3     | ANAPOE<sup>1</sup>-C13E8      | 0.1% w/v                       | +++      |
| 4     | C12E8                          | 0.11 mM                        | +++      |
| 5     | ANAPOE<sup>1</sup>-C12E10     | 1% w/v                         | +++      |
| 6     | Sucrose monolaurate            | 0.3 mM                         | +++      |
| 7     | n-Undecyl-b-D-maltoside       | 0.59 mM                        | ++       |
| 8     | CYMAL<sup>1</sup>-6           | 0.56 mM                        | +++      |
| 9     | n-Nonyl-b-D-thiogluoside       | 0.15 mM                        | ++       |
| 10    | CYMAL<sup>1</sup>-5           | 5 mM                            | ++       |
| 11    | n-Nonyl-β-D-maltoside         | 6 mM                            | ++       |
| 12    | C8E4                           | 8 mM                            | ++       |
| 13    | C-HEGA<sup>1</sup>-11         | 11.5 mM                        | ++       |
| 14    | n-Octyl-β-D-glucoside         | 20 mM                           | ++       |
| 15    | MEGA-9                         | 25 mM                           | +        |
| 16    | 2,6-Dimethyl-4-heptyl-β-D-maltopyranoside | 27.5 mM | +++ |
| 17    | C-HEGA<sup>1</sup>-10         | 35 mM                           | 0        |
| 18    | HEGA<sup>1</sup>-9            | 39 mM                           | +        |
| 19    | C-HEGA<sup>1</sup>-9          | 108 mM                          | 0        |
| 20    | HEGA<sup>1</sup>-8            | 109 mM                          | 0        |
| 21    | CYMAL<sup>1</sup>-2           | 120 mM                          | 0        |
| 22    | n-Hexyl-β-D-glucopyranoside   | 250 mM                          | +        |
| 23    | NDSB-195                       | 50 mM                           | +++      |
| 24    | FOS-Choline<sup>1</sup>-12    | 1.5 mM                          | ++       |
| 25    | FOS-Choline<sup>1</sup>-8, fluorinated | 2.2 MM | ++ |
| 26    | ZWITTERGENT<sup>1</sup>-3–12  | 4 mM                            | +        |
| 27    | CHAPS                          | 8 mM                            | ++       |
| 28    | CHAPSO                         | 8 mM                            | ++       |
| 29    | n-Decyl-N,N-dimethylglycine    | 18 mM                           | 0        |
| 30    | ANAPOE<sup>1</sup>-58         | 1% w/v                          | ++       |
| 31    | MEGA -10                       | 7 mM                            | +        |
| 32    | CYMAL<sup>1</sup>-4           | 7.6 mM                          | ++       |
| 33    | Pluronic<sup>1</sup> F-68      | 1% w/v                          | +        |
| 34    | HECAMEG<sup>1</sup>           | 19.5 mM                         | +        |
| 35    | Sulfobetaine 3–10              | 25 mM                           | ++       |
| 36    | CYMAL<sup>1</sup>-3           | 34.5 mM                         | +        |
| 37    | MEGA-8                         | 79 mM                           | 0        |
| 38    | NDSB-256                       | 50 mM                           | +        |
| 39    | DDMAB                          | 4.3 mM                          | +++      |
| 40    | FOS-MEA<sup>1</sup>-10        | 5.2 mM                          | +        |
| 41    | ZWITTERGENT<sup>1</sup>-3–10  | 40 mM                           | +++      |
| 42    | FOS-Choline<sup>1</sup>-8     | 114 mM                          | 0        |
| 43    | LysoFos™ Choline 12            | 0.7 mM                          | +        |
| 44    | LysoFos™ Choline 10            | 7 mM                            | +++      |
| 45    | Sodium dodecanoylsarcosine     | 14.4 mM                         | +        |
| 46    | ANAPOE<sup>1</sup>-20         | 1% w/v                          | ++       |
| 47    | n-Dodecyl-β-D-maltoside       | 0.17 mM                         | +++      |

(Continued)
protein, reducing electrostatic attraction between proteins and thereby enhancing the solubility of the target protein. This suggests that a defined amount of salt in buffers is required for the stability and solubility of proteins. We tested the cleavage of His8-MBP-HRV 3C-MTD by the HRV 3C protease in presence of increasing concentrations of NaCl, KCl, CaCl2, MgCl2, MgSO4 and ZnSO4. With the exception of ZnSO4, none of the salt ions inhibited the activity of the HRV 3C protease at concentrations between 0.05 and 0.4 M (Fig 3).

Additives like sorbitol, trehalose, glycerol, arginine and proline are added during the extraction and purification of proteins to aid solubilization [10]. Fig 3 shows only limited effects

![HRV 3C protease](image)

![TEV protease](image)

Fig 1. Analysis of activities of the HRV 3C and TEV proteases at 25°C towards their target proteins (His8-MBP-HRV 3C-MTD or His8-MBP-TEV-MTD, His8-MBP-HRV 3C-betaC1 or His8-MBP-TEV-beta C1 and His8-HRV 3C-100K or His8-TEV-100K). Respective cleavable fusion proteins were incubated with HRV 3C protease or TEV protease at ratio of 50:1 for 1 hour and analysed by SDS-PAGE. “U” and “T” represent the cleavable fusion protein untreated and treated, respectively, with the HRV 3C or TEV protease. Note: in case of cleavage of 100K fusion protein, 2kDa band was not observed because of low %age of polyacrylamide used in SDS-PAGE.

Table 3. (Continued)

| S.No. | Chemical Name   | Critical micelle concentration | Activity |
|-------|-----------------|--------------------------------|----------|
| 48    | TRITON® X-100   | 0.9 mM                         | +++      |
| 49    | LDAO            | 2 mM                           | ++       |

doi:10.1371/journal.pone.0153436.t003
upon adding these molecules into the cleavage reaction; hence, their removal is not necessary prior to cleavage. Strong denaturants like SDS at tested concentration of 0.13% and also guanidine-HCl when present above 0.5 M severely inhibited the activity of the HRV 3C protease (Fig 3). However, the HRV 3C protease exhibited optimal activity towards the target protein in the presence of urea up to a concentration of 2 M (Fig 3). Higher urea concentrations might impair HRV 3C protease activity also, however, these were not tested in this study. The reducing agents β-ME, DTT and TCEP are often used to maintain the activity and the stability of target proteins or to prevent protein aggregation. HRV 3C protease activity persisted in the presence of up to 50 mM β-ME, 100 mM DTT and 5 mM TCEP, which are up to or far above typical concentrations used in recombinant protein production (Fig 3).

Finally, we assessed the activity of the HRV 3C protease in the presence of different detergents at 4°C. These chemicals are used for different purposes, including the extraction of hydrophobic proteins from biological membranes, refolding, crystallization and protein stabilization. We digested His8-MBP-HRV 3C-MTD in the presence of various detergents at their critical micelle concentration with HRV 3C protease (Table 3 and Fig 4). Of the forty nine detergents tested, fourteen detergents (ANAPOE®-80, n-Tetradecyl-β-D-maltoside, ANAPOE®-C13E8, C12E8, ANAPOE®-C12E10, Sucrose monolaurate, CYMAL®-6,
Fig 3. SDS-PAGE showing the HRV 3C protease activity in the presence of various buffers, increasing concentrations of variety of salts, additives and detergents commonly used during extraction and purification of proteins. “C” represents the cleavable fusion protein treated with protease in the absence of any additive.

doi:10.1371/journal.pone.0153436.g003
2,6-Dimethyl-4-heptyl-β-D-maltopyranoside, NDSB-195, DDMAB, ZWITTERGENT® 3–10, LysoFos™ Choline 10, n-Dodecyl-β-D-maltoside and TRITON® X-100) did not affect the HRV 3C protease activity and the target protein was efficiently cleaved (~ 80 to 100%) compared to a control reaction in absence of any detergent. In the presence of fifteen...
detergents (n-Undecyl-β-D-maltoside, n-Nonyl-β-D-thioglucoside, CYMAL®-5, n-Nonyl-β-D-maltoside, C8E4, C-HEGA®-11, n-Octyl-β-D-glucoside, FOS-Choline®-12, FOS-Choline®-8 fluorinated, CHAPS, CHAPSO, ANAPOE®-58, CYMAL®-4, Sulfo betaine 3–10 and LDAO) HRV 3C protease activity was reduced to ~ 50% relative to the control reaction and the activity decreased further, below 50%, relative to the cleavage in the control reaction in the presence of another twelve detergents (MEGA-9, HEGA®-9, n-Hexyl-β-D-glucopyranoside, ZWITTERGENT® 3–12, MEGA-10, Pluronic® F-68, HECAMEG®, CYMAL®-3, NDSB-256, FOS-MEA®-10, LysoFos” Choline 12, and Sodium dodecanoylsarcosine). HRV 3C protease activity was completely abolished in the presence of eight detergents (C-HEGA®-10, C-HEGA®-9, HEGA®-8, CYMAL®-2, n-Decyl-N,N-dimethylglycine, MEGA-8, FOS-Choline®-8 and ANAPOE®-20). In 2011, Vergis and Weiner [4] reported a study on the cleavage activity of HRV 3C protease in the presence of a wide range of detergents at 25°C. Although the substrates are different and half of the detergents tested are different, comparison of both datasets for the same detergents show that, in most cases, HRV 3C protease activity is preserved better at 4°C. For example, whereas Vergis and Weiner [4] report little or no cleavage in the presence of FOS-choline-12, HRV 3C protease cleaves over 50% of the target protein at 4°C. In contrast, cleavage is better at 25°C in the presence of C8E4, HECAMEG and n-undecyl-β-D-maltoside [4]. On the basis of structure of detergents, it has been observed that HRV 3C protease is inhibited to less extent by maltoside and glycol ether containing detergents.

The extent to which the HRV 3C protease has cleaved His8-MBP-HRV 3C-domain in presence of various detergents at their critical micelle concentration is shown in Fig 3 and represented as follows ‘+++’ for cleavage ~ 80 to 100%, ‘++’ for ~ 50% and ‘+’ for <50%, ‘0’ for almost no cleavage at all compared to control. Critical micelle concentration of detergents was taken from http://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Sigma/Instructions/detergent_selection_table.pdf

We show that HRV 3C protease activity is insensitive to frequently used buffers and additives in recombinant protein production. Importantly, our results demonstrate the superior cleavage properties of HRV 3C protease at 4°C, a temperature of choice for the processing of many proteins, though dataset was comprised of only three fusion proteins. These characteristics make HRV 3C protease the protease of choice for the removal of tags from fusion proteins. This is of relevance for HRV 3C protease to be exploited to enhance the large-scale production of proteins of industrial and pharmaceutical importance.

Acknowledgments

We thank Samar Hasnain, University of Liverpool, UK for provision of TEV protease construct and Andreas Engel, Case Western Reserve University, USA for HRV 3C construct. We thank Gerard Huysmans for critical comments and for improving the manuscript. This work was supported by the International Centre for Genetic Engineering and Biotechnology, Italy [grant No. CRP/PAK10-01; (awarded to M. Rahman)] and PhD studentships by Higher Education Commission of Pakistan (awarded to Raheem Ullah and Majid Ali Shah).

Author Contributions

Conceived and designed the experiments: MR RU MAS M. Imran M. Iqbal. Performed the experiments: RU MAS ST FI. Analyzed the data: MR OM RU MAS ST FI M. Imran. Contributed reagents/materials/analysis tools: MR M. Imran OM. Wrote the paper: MR OM RU MS M. Imran M. Iqbal.
References

1. Young CL, Britton ZT, Robinson AS. Recombinant protein expression and purification: a comprehensive review of affinity tags and microbial applications. Biotechnol. J. 2012; 7: 620–634. doi: 10.1002/biot.201100155 PMID: 22442034

2. Waugh DS. An overview of enzymatic reagents for the removal of affinity tags. Protein Expr Purif. 2011; 80: 283–293. doi: 10.1016/j.pep.2011.08.005 PMID: 21871965

3. Walker PA, Leong LEC, Ng PWP, Tan SH, Wailer S, Murphy D, Porter AG, et al. Efficient and rapid Affinity purification of proteins using recombinant fusion proteases. Bio-Technology. 1994; 12: 601–605. PMID: 7764949

4. Vergis JM, Wiener MC. The variable detergent sensitivity of proteases that are utilized for recombinant protein affinity tag removal. Protein Expr Purif. 2011; 80: 283–293. doi: 10.1016/j.pep.2011.08.005 PMID: 21871965

5. Sun CS, Liang JQ, Shi R, Gao XN, Zhang RJ, Hong FL, et al. Tobacco etch virus protease retains its activity in various buffers and in the presence of diverse additives. Protein Expr Purif. 2012; 82: 139–14. doi: 10.1016/j.pep.2011.04.011 PMID: 21539919

6. Cordingley MG, Callaham PL, Sardana VV, Garsky VM, Colonno RJ. Substrate requirements of human rhinovirus 3C protease for peptide cleavage in vitro. J Biol Chem. 1990; 265: 9062–9065. PMID: 2160953

7. Leong LE. The use of recombinant fusion proteases in the affinity purification of recombinant proteins. Mol Biotechnol. 1999; 12: 269–274. PMID: 10631683

8. Wang QM, Johnson RB. Activation of human rhinovirus-14 3C protease. Virology. 2001; 280: 80–86. PMID: 11162821

9. Smyth DR, Mrozkiwicz MK, McGrath WJ, Listwan P, Kobe B. (2003) Crystal structures of fusion proteins with large-affinity tags. Protein Sci. 2003; 12: 1313–1322. PMID: 12624478

10. Leiby DJ, Nguyen TN, Kao LT, Hewitt SN, Barrett LR, Van Voorhis WC. Stabilizing additives added during cell lysis in the solubilization of recombinant proteins. PLOS One. 2012; 7: e52482. doi: 10.1371/journal.pone.0052482 PMID: 23285060

11. Ruckenstein E, Shulgin IL. Effect of salts and organic additives on the solubility of proteins in aqueous solutions, Advances in Colloid and Interface. Science. 2006; 123: 97–103.

12. Lundback AK, van den Berg S, Hebert H, Berglund H, Eshaghi S, Exploring the activity of tobacco etch virus protease in detergent solutions. Anal Biochem. 2008; 382: 69–71. doi: 10.1016/j.ab.2008.07.018 PMID: 18682245

13. Mohanty AK, Simmons CR, Wiener MC. Inhibition of tobacco etch virus protease activity by detergents. Protein Expr Purif. 2003; 27: 109–114. PMID: 12509992

14. Rocco CJ, Dennison KL, Klenchin VA, Raymont I, Escalante-Semerena JC. Construction and use of new cloning vectors for the rapid isolation of recombinant proteins from Escherichia coli. Plasmid. 2008; 59: 231–237. doi: 10.1016/j.plasmid.2008.01.001 PMID: 18295882

15. Iram N, Shah MS, Ismat F, Habib M, Iqbal M, Hasan SS, et al. Heterologous expression, characterization and evaluation of the matrix protein from Newcastle disease virus as a target for antiviral therapies. Appl Microbiol Biotechnol. 2013; 98: 1691–1701. PMID: 23797330

16. Miroux B, Walker JE. Over-production of proteins in Escherichia coli: mutant hosts that allow synthesis of some membrane proteins and globular proteins at high levels. J Mol Biol 1996; 260: 289–98. PMID: 8757792

17. Shah MS, Ashraf A, Khan MI, Rahman M, Habib M, Qureshi JA. Molecular cloning, expression and characterization of 100K gene of fowl adenovirus-4 for prevention and control of hydropericardium syndrome. Biologicals. 2016; 44: 19–23. doi: 10.1016/j.biologicals.2015.10.002 PMID: 26558992

18. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72: 248–254. PMID: 942051

19. Chi EY, Krishnan S, Randolph TW, Carpenter JF. Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res. 2003; 20: 1325–1336. PMID: 14567625

20. Block H, Maertens B, Spriestersbach A, Brinker N, Kubicek J, Fabis R, et al. Immobilized-metal affinity chromatography (IMAC): a review. Methods Enzymol. 2009; 463: 439–473. doi: 10.1016/S0076-6879 (09)63027-5 PMID: 19892187

21. Schmidt TGM, Skerra A, The Strept-tag system for one-step purification and high-affinity detection or capturing of proteins. Nat Protoc. 2007; 1528–1535. PMID: 17571060

22. Riggs P. Expression and purification of maltose-binding protein fusions. Curr Protoc Mol Biol. 2001. 16.
23. Simons PC, Vander Jagt DL. Purification of glutathione S-transferases by glutathione-affinity chromatography. Methods Enzymol. 1981; 77: 235. PMID: 7329302

24. Mao YJ, Sheng XR, Pan XM. The effects of NaCl concentration and pH on the stability of hyperthermophilic protein Ssh10b, BMC Biochemistry. 2007; 8: 28. PMID: 18096085